DEA Blocks California Doc from Prescribing Controlled Drugs
Published Date: 4/1/2025
Notice
Summary
The DEA has officially denied Dr. Phong H. Tran’s application to register for handling controlled substances in California because he’s excluded from federal health programs and lacks state permission. This means Dr. Tran can’t legally prescribe or manage certain drugs, impacting his medical practice and patients. The decision is final as of April 1, 2025, and no appeals were filed.
Analyzed Economic Effects
3 provisions identified: 0 benefits, 3 costs, 0 mixed.
DEA Registration Denied for Dr. Tran
The Drug Enforcement Administration denied Phong H. Tran, M.D.'s application for a DEA Certificate of Registration, Control No. W22138631C, in California and also denied any other pending application of his for additional registration in California. The Order is issued under 21 U.S.C. 823(g)(1) and 824(a)(5) and states it will be effective thirty days after publication in the Federal Register.
California Medical License Revoked
The Medical Board of California revoked Respondent's California medical license effective August 2, 2024, and California online records taken official notice show the license remains revoked. Because he is not licensed to practice medicine in California, DEA found he lacks the state authority required to obtain or maintain a DEA registration to handle controlled substances in that state.
Mandatory Exclusion From Federal Health Programs
The U.S. Department of Health and Human Services, Office of Inspector General excluded Respondent from participation in Medicare, Medicaid, and all federal health care programs effective September 20, 2022, for a period of twelve years. DEA treated that mandatory exclusion under 42 U.S.C. 1320a-7(a) and 21 U.S.C. 824(a)(5) as a separate, independent basis to deny his DEA registration application.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-11572 — Ashley Vermillion, N.P.; Decision and Order
Ashley Vermillion, a nurse practitioner from Maine, lost her DEA registration because she no longer has the legal right to handle controlled substances in her state. She didn’t ask for a hearing, so the DEA moved forward and officially revoked her registration. This means she can’t prescribe or manage controlled drugs anymore, effective immediately.
2026-11416 — Importer of Controlled Substances Application: CalCog Inc.
CalCog Inc. wants to become an official importer of some powerful controlled substances like LSD and 5-MeO-DMT. People and companies involved with these drugs have until July 8, 2026, to share their thoughts or ask for a hearing. This move could shake up the import scene, but no costs or changes happen until the DEA decides.
2026-10380 — Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
The DEA wants to put diphenidine, a drug, into Schedule I, which means it will be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or owns diphenidine, adding strict rules and penalties. You’ve got until June 25, 2026, to share your thoughts before the new rules might kick in.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
Previous / Next Documents
Previous: 2025-05525 — Notice of Intent To Rule on a Land Release Request for Disposal of Airport Property at Dinwiddie County Airport, Petersburg, VA
The FAA is thinking about approving a request to sell 44.24 acres of land at Dinwiddie County Airport in Petersburg, VA. This change affects the airport and local community, but the land will still be used in a way that works well with the airport. People can share their thoughts before the FAA makes a final decision.
Next: 2025-05527 — Baijes Bissonnet Pharmacy; Decision and Order
Baijes Bissonnet Pharmacy in Texas tried to get a DEA registration but got denied because they filled risky prescriptions without fixing warning signs. They missed the deadline to ask for a hearing, so the DEA’s decision stands. This means the pharmacy can’t legally handle certain controlled medicines, affecting their business and customers right away.